SavedAdd your journal

Journals / Turkish Journal of Clinics and Laboratory / 2026 / Sayı: 1

Retrospective evaluation of the efficacy and safety of granulocyte colony-stimulating factor use in extensive-stage small cell lung cancer

Granülosit koloni stimülan faktörün yaygın evre küçük hücreli akciğer kanserinde etkinlik ve güvenilirliğinin retrospektif analizi

Güner Akgüner(Ankara Etlik şehir hastanesi)0000-0001-6400-317X
Galip Can Uyar(etlik şehir hastanesi)0000-0002-0698-777X
Kadriye Başkurt(etlik şehir hastanesi)0000-0002-6091-730X
Osman Sütçüoğlu(etlik şehir hastanesi)0000-0003-3835-2741
Pages
—
Publication Date
2026-02-04
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients were categorized based on G-CSF use, and overall survival (OS) and progression-free survival (PFS) were compared between groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Extensive-stage small cell lung cancer (ES-SCLC) is associated with a poor prognosis, with platinum-based chemotherapy being the mainstay of treatment.
📊
Key Findings & Data:Materials and Methods: This single-center retrospective study included 80 patients.
💡
Conclusion & Impact:Patients were categorized based on G-CSF use, and overall survival (OS) and progression-free survival (PFS) were compared between groups.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:küçük hücreli akciğer kanseri · G-CSF · kemoterapi

Abstract

Aim: Extensive-stage small cell lung cancer (ES-SCLC) is associated with a poor prognosis, with platinum-based chemotherapy being the mainstay of treatment. Chemotherapy-induced neutropenia can lead to treatment delays and hospitalizations due to febrile neutropenia. The use of granulocyte colony-stimulating factor (G-CSF) reduces the incidence of chemotherapy-induced neutropenia and febrile neutropenia. This study aims to evaluate the impact of G-CSF use on prognosis and its safety in extensive-stage SCLC. Materials and Methods: This single-center retrospective study included 80 patients. Patients were categorized based on G-CSF use, and overall survival (OS) and progression-free survival (PFS) were compared between groups. Univariate and multivariate analyses were performed using the Cox regression model to identify prognostic factors. The safety of G-CSF use was also evaluated. Results: The median OS was 11.0 months in the G-CSF group and 8.6 months in the non-G-CSF group (p = 0.026). The median PFS was 8.0 months in the G-CSF group and 7.0 months in the non-G-CSF group (p = 0.044). The median OS was 15.1 months in the primary prophylaxis group and 10.2 months in the secondary prophylaxis group (p = 0.099). The median PFS was 10.0 months in the primary prophylaxis group and 7.4 months in the secondary prophylaxis group (p = 0.014). In the multivariate analysis, G-CSF use was identified as an independent prognostic factor for longer overall survival (OS) (HR: 0.51; 95% CI: 0.28–0.90, p = 0.021) and progression-free survival (PFS) (HR:0.57, 95% CI: 0.34-0.95, p = 0.031). No adverse events related to G-CSF use were observed in 69 patients (86.3%). Severe adverse event (grade 3) (thrombocytopenia) was observed in only 1 patient (1.3%). Conclusion: In the current study, the use of G-CSF was found to improve overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC). Further large-scale prospective studies are needed to support these findings.

Özet

Amaç: Yaygın evre küçük hücreli akciğer kanseri (ES-SCLC), kötü prognozlu olup tedavisinde platin bazlı kemoterapi temel yaklaşımdır. Kemoterapinin yol açtığı nötropeni, febril nötropeni nedeniyle tedavi gecikmelerine ve hastaneye yatışlara neden olabilir. Granülosit koloni uyarıcı faktör (G-CSF) kullanımı, kemoterapiye bağlı nötropeni ve febril nötropeni insidansını azaltmaktadır. Bu çalışmanın amacı, ES-SCLC'de G-CSF kullanımının prognoz üzerindeki etkisini ve güvenilirliğini değerlendirmektir. Gereç ve Yöntemler: Bu tek merkezli, retrospektif çalışmaya 80 hasta dahil edilmiştir. Hastalar G-CSF kullanımına göre sınıflandırılmış ve genel sağkalım (OS) ile progresyonsuz sağkalım (PFS) gruplar arasında karşılaştırılmıştır. Prognoza etki eden faktörleri belirlemek amacıyla Cox regresyon modeli kullanılarak tek değişkenli ve çok değişkenli analizler yapılmıştır. G-CSF kullanımının güvenilirliği de değerlendirilmiştir. Bulgular: G-CSF grubunda medyan genel sağkalım (OS) 11,0 ay, G-CSF kullanılmayan grupta 8,6 aydı (p = 0,026). Medyan progresyonsuz sağkalım (PFS) G-CSF grubunda 8,0 ay, G-CSF kullanılmayan grupta 7,0 aydı (p = 0,044). Primer profilaksi grubunda medyan OS 15,1 ay, sekonder profilaksi grubunda ise 10,2 aydı (p = 0,099). Medyan PFS primer profilaksi grubunda 10,0 ay, sekonder profilaksi grubunda 7,4 aydı (p = 0,014). Multivariate analizde G-CSF kullanımı, daha uzun genel sağkalım (OS) (HR: 0,51; %95 CI: 0,28–0,90, p = 0,021) ve progresyonsuz sağkalım (PFS) (HR:0,57, %95 CI: 0,34-0,95, p = 0,031) için bağımsız bir prognostik faktör olarak tanımlandı. G-CSF kullanımına bağlı olarak 69 hastada (%86.3) herhangi bir advers olay gözlenmeyip, sadece 1 hastada (%1,3) ciddi (Grade 3) advers olay (trombositopeni) saptandı. Sonuç: Bu çalışmada, yaygın evre küçük hücreli akciğer kanseri (ES-SCLC) hastalarında G-CSF kullanımının genel sağkalımı iyileştirdiği bulunmuştur. Bu bulguları desteklemek için daha geniş ölçekli prospektif çalışmalara ihtiyaç duyulmaktadır.

🔖

Cite This Article

Akgüner, G., Uyar, G. C., Başkurt, K., Sütçüoğlu, O. (2026). Retrospective evaluation of the efficacy and safety of granulocyte colony-stimulating factor use in extensive-stage small cell lung cancer. Turkish Journal of Clinics and Laboratory, Sayı: 1. https://doi.org/10.18663/tjcl.1800650

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (35)

  1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17–48.
  2. Basumallik N, Agarwal M. Small Cell Lung Cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
  3. Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2013; 24: 2475–84.
  4. Weycker D, Barron R, Edelsberg J, Kartashov A, Legg J, Glass AG. Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis. BMC Health Serv Res 2014; 14: 189.
  5. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor. Eur J Cancer 2011; 47: 8–32.
  6. Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R et al. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. J Natl Compr Canc Netw 2020; 18: 12–22.
  7. Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al. Recommendations for the use of WBC growth factors: ASCO clinical practice guideline update. J Clin Oncol 2015; 33: 3199–212.
  8. Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016; 27: v111–8.
  9. Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R et al. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2022. J Natl Compr Canc Netw 2022; 20: 436–42.
  10. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002; 62: 1–15.
  11. Clemons M, Fergusson D, Simos D, Mates M, Robinson A, Califaretti N et al. A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer. Ann Oncol 2020; 31: 951–7.
  12. Amgen Canada Inc. Product Monograph (filgrastim); 2016.
  13. Hendler D, Rizel S, Yerushalmi R, Neiman V, Bonilla L, Braunstein R et al. Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized study. Am J Clin Oncol 2011; 34: 619–24.
  14. Yang X, Liu F, Xu Z, Chen C, Wu X, Li G et al. Expression of granulocyte colony stimulating factor receptor in human colorectal cancer. Postgrad Med J 2005; 81: 333–7.
  15. Fukui Y, Kawashima M, Kawaguchi K, Takeuchi M, Hirata M, Kataoka TR et al. Granulocyte-colony-stimulating factor-producing metaplastic carcinoma of the breast with significant elevation of serum interleukin-17 and vascular endothelial growth factor levels. Int Cancer Conf J 2018; 7: 107–13.
  16. Sato N, Asano S, Ueyama Y, Mori M, Okabe T, Kondo Y et al. Granulocytosis and CSA produced by a human squamous cell carcinoma. Cancer 1979; 43: 605–10.
  17. Karagiannidis I, Salataj E, Said Abu Egal E, Beswick EJ. G-CSF in tumors: aggressiveness and immune regulation. Cytokine 2021; 142: 155479.
  18. Tsukazaki Y, Ogino H, Okano Y, Kakiuchi S, Harada S, Toyoda Y et al. Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer. Int J Clin Oncol 2024; 29: 1451–60.
  19. Gomes F, Faivre-Finn C, Mistry H, Bezjak A, Pourel N, Fournel P et al. Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial. Lung Cancer 2021; 153: 165–70.
  20. Wang C, Zhu S, Miao C, Wang Y, Chen J, Yuan S et al. Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial. BMC Cancer 2022; 22: 542.
  21. Ilhan Y, Ucar G, Baser MN, Guzel HG, Efil SC, Demir B et al. Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy. Expert Opin Pharmacother 2024; 25: 1555–63.
  22. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78: 2791–808.
  23. Panopoulos AD, Watowich SS. Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine 2008; 42: 277–88.
  24. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25: 3158–67.
  25. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I et al. Filgrastim in the prevention of neutropenia and associated infection after chemotherapy. N Engl J Med 1991; 325: 164–70.
  26. Gatzemeier U, Kleisbauer JP, Drings P, Kaukel E, Samaras N, Melo MJ et al. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol 2000; 23: 393–400.
  27. Lyman GH, Reiner M, Morrow PK, Crawford J. The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. Ann Oncol 2015; 26: 1452–8.
  28. Lee YS, Saxena V, Bromberg JS, Scalea JR. G-CSF promotes alloregulatory function of MDSCs through a c-Kit dependent mechanism. Cell Immunol 2021; 364: 104346.
  29. Fischer OW, Justesen TF, Gögenur DS, Madsen MT, Mortensen MB, Gögenur I, Orhan A. Long Term Oncological Outcomes of Granulocyte Colony Stimulating Factor Treatment in Gastrointestinal Cancers: A Systematic Review and Meta Analysis. Cancers (Basel) 2025; 17: 1313.
  30. Wang L, Baser O, Kutikova L, Page JH, Barron RL. The impact of primary prophylaxis with granulocyte colony stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta analysis of randomized controlled trials. Blood 2014; 124: 4850.
  31. Campbell K, Chadha N, Dimri S, Wang W, Li E. G CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review. Expert Rev Hematol 2022; 15: 619–33.
  32. Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer 2018; 26: 7–20.
  33. Frampton JE, Lee CR, Faulds D. Filgrastim. Drugs 1994; 48: 731–60.
  34. Kaur A, Wang S, Jayarangaiah A, Malone M, Yu A, Kumar A. Real World Risk of Splenic Rupture with G CSF/GM CSF Therapy: A Pharmacovigilance Assessment Using the FDA Adverse Event Reporting System. Blood 2020; 136: 32–3.
  35. Lapidari P, Vaz-Luis I, Di Meglio A. Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review. Crit Rev Oncol Hematol 2021; 157: 103193.